Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

How Stigma and Socioeconomic Barriers Impede HCV Care: Conversations Between Patient and Physician

This episode features a conversation between a patient, Alicia, and Oluwaseun Falade-Nwulia, MBBS, MPH, who discuss how stigma in the medical system toward marginalized populations, including people who inject drugs or who have a history of injection drug use, prevents access to HCV care.
Oluwaseun Falade-Nwulia, MBBS, MPH
Released: April 20, 2022

In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and a patient with previous injection drug use who has been cured of HCV infection discuss critical barriers that are preventing more people with current or previous injection drug use from receiving appropriate HCV care.

This insightful discussion underscores the negative effects of stigma toward people who inject drugs that exist in many clinical settings, the important role that socioeconomic factors such as transportation access and stable housing play in preventing access to HCV care, the effects of insufficient staffing at many addiction treatment centers, and the need for creative solutions to overcome these barriers.

Information on this Educational Activity

Faculty

Oluwaseun Falade-Nwulia, MBBS, MPH

Associate Professor
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Attending
Division of Infectious Diseases
Johns Hopkins Hospital
Baltimore, Maryland

Oluwaseun Falade-Nwulia MBBS, MPH, has disclosed that she has received consulting fees from Gilead Sciences and funds for research support from AbbVie.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Clinical Care Options (CCO) expert analysis by Prof Tarik Asselah on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Tarik Asselah, MD, PhD Released: July 8, 2022

Clinical Care Options (CCO) expert analysis by Prof Stefan Zeuzem on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings